Arena Pharmaceuticals Inc logo

ARNA - Arena Pharmaceuticals Inc Share Price

$64.76 -1.5  -2.3%

Last Trade - 9:00pm

Large Cap
Market Cap £2.92bn
Enterprise Value £2.15bn
Revenue £233k
Position in Universe 1604th / 6825
Unlock ARNA Revenue
Relative Strength (%)
1m -13.6%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -26.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
13.4 92.2 21.3 18.0 806.4 0.32 23.3 61.6 -52.6%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, ArenaPharmaceuticals, Inc. revenues decreased 100% to $319K. Netloss totaled $404.7M vs. income of $397.6M. Revenuesreflect United Therapeutics revenue decrease from $800M to$0K, Collaboration and other revenue decrease of 99% to$57K. Net loss reflects Salary And other personal Costsincrease from $48K to $64.7M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ARNA Revenue Unlock ARNA Revenue

Net Income

ARNA Net Income Unlock ARNA Revenue

Normalised EPS

ARNA Normalised EPS Unlock ARNA Revenue

PE Ratio Range

ARNA PE Ratio Range Unlock ARNA Revenue

Dividend Yield Range

ARNA Dividend Yield Range Unlock ARNA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ARNA EPS Forecasts Unlock ARNA Revenue
Profile Summary

Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated April 14, 1997
Public Since July 28, 2000
No. of Shareholders: 81
No. of Employees: 363
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 60,334,648
Free Float (0.0%)
Eligible for
ARNA Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ARNA
Upcoming Events for ARNA
Wednesday 5th May, 2021 Estimate
Q1 2021 Arena Pharmaceuticals Inc Earnings Release
Friday 11th June, 2021 Estimate
Arena Pharmaceuticals Inc Annual Shareholders Meeting
Tuesday 3rd August, 2021 Estimate
Q2 2021 Arena Pharmaceuticals Inc Earnings Release
Frequently Asked Questions for Arena Pharmaceuticals Inc
What is the Arena Pharmaceuticals Inc share price?

As of 9:00pm, shares in Arena Pharmaceuticals Inc are trading at $64.76, giving the company a market capitalisation of £2.92bn. This share price information is delayed by 15 minutes.

How has the Arena Pharmaceuticals Inc share price performed this year?

Shares in Arena Pharmaceuticals Inc are currently trading at $64.76 and the price has moved by 40.15% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Arena Pharmaceuticals Inc price has moved by -5.54% over the past year.

What are the analyst and broker recommendations for Arena Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Arena Pharmaceuticals Inc, there are there are currently 4 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Arena Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Arena Pharmaceuticals Inc next release its financial results?

Arena Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Arena Pharmaceuticals Inc dividend yield?

Arena Pharmaceuticals Inc does not currently pay a dividend.

Does Arena Pharmaceuticals Inc pay a dividend?

Arena Pharmaceuticals Inc does not currently pay a dividend.

When does Arena Pharmaceuticals Inc next pay dividends?

Arena Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Arena Pharmaceuticals Inc shares?

To buy shares in Arena Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Arena Pharmaceuticals Inc?

Shares in Arena Pharmaceuticals Inc are currently trading at $64.76, giving the company a market capitalisation of £2.92bn.

Where are Arena Pharmaceuticals Inc shares listed? Where are Arena Pharmaceuticals Inc shares listed?

Here are the trading details for Arena Pharmaceuticals Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ARNA
What kind of share is Arena Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Arena Pharmaceuticals Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Arena Pharmaceuticals Inc share price forecast 2021?

Shares in Arena Pharmaceuticals Inc are currently priced at $64.76. At that level they are trading at 44.94% discount to the analyst consensus target price of 0.00.

Analysts covering Arena Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -8.175 for the next financial year.

How can I tell whether the Arena Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arena Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -30.75%. At the current price of $64.76, shares in Arena Pharmaceuticals Inc are trading at -8.46% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Arena Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Arena Pharmaceuticals Inc.

Who are the key directors of Arena Pharmaceuticals Inc?

Arena Pharmaceuticals Inc's management team is headed by:

Amit Munshi - PRE
Vincent Aurentz - EVP
Jayson Dallas - IND
Oliver Fetzer - IND
Garry Neil - NEC
Robert Lisicki - EVP
Laurie Stelzer - CFO
Joan Schmidt - EVP
Katharine Knobil - DRC
Paul Streck - SVP
Nawal Ouzren - DRC
Who are the major shareholders of Arena Pharmaceuticals Inc?

Here are the top five shareholders of Arena Pharmaceuticals Inc based on the size of their shareholding:

Wellington Management Company, LLP Investment Advisor/Hedge Fund
Percentage owned: 10.42% (6.29m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 8.72% (5.26m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 7.04% (4.25m shares)
Avoro Capital Advisors LLC Investment Advisor/Hedge Fund
Percentage owned: 6.94% (4.19m shares)
State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 3.43% (2.07m shares)
Similar to ARNA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.